Skip to main content Back to Top
Advertisement

8/9/2019

Buspirone Tablets

Products Affected - Description

    • Buspirone tablet, Accord, 10 mg, bottle, 100 count, NDC 16729-0202-01
    • Buspirone tablet, Accord, 10 mg, bottle, 500 count, NDC 16729-0202-16
    • Buspirone tablet, Accord, 15 mg, bottle, 60 count, NDC 16729-0203-12
    • Buspirone tablet, Accord, 15 mg, bottle, 100 count, NDC 16729-0203-01
    • Buspirone tablet, Accord, 30 mg, bottle, 60 count, NDC 16729-0289-12
    • Buspirone tablet, Accord, 5 mg, bottle, 100 count, NDC 16729-0200-01
    • Buspirone tablet, Accord, 5 mg, bottle, 500 count, NDC 16729-0200-16
    • Buspirone tablet, Teva, 10 mg, bottle, 100 count, NDC 00093-0054-01
    • Buspirone tablet, Teva, 10 mg, bottle, 500 count, NDC 00093-0054-05
    • Buspirone tablet, Teva, 15 mg, bottle, 100 count, NDC 00093-1003-01
    • Buspirone tablet, Teva, 30 mg, bottle, 500 count, NDC 00093-5200-05
    • Buspirone tablet, Zydus, 10 mg, bottle, 100 count, NDC 68382-0181-01
    • Buspirone tablet, Zydus, 10 mg, bottle, 500 count, NDC 68382-0181-05
    • Buspirone tablet, Zydus, 15 mg, bottle, 100 count, NDC 68382-0182-01
    • Buspirone tablet, Zydus, 15 mg, bottle, 500 count, NDC 68382-0182-05
    • Buspirone tablet, Zydus, 30 mg, bottle, 60 count, NDC 68382-0183-14
    • Buspirone tablet, Zydus, 30 mg, bottle, 500 count, NDC 68382-0183-05
    • Buspirone tablet, Zydus, 5 mg, bottle, 100 count, NDC 68382-0180-01
    • Buspirone tablet, Zydus, 5 mg, bottle, 500 count, NDC 68382-0180-05

Reason for the Shortage

    • Accord did not provide a reason for the shortage.
    • Mylan refuses to provide updated availability information.
    • Par has buspirone tablets available.
    • Teva did not provide a reason for the shortage.
    • Zydus did not provide a reason for the shortage.

Available Products

    • Buspirone tablet, Par Pharmaceuticals, 7.5 mg, bottle, 100 count, NDC 49884-0725-01
    • Buspirone tablet, Par Pharmaceuticals, 7.5 mg, bottle, 500 count, NDC 49884-0725-05
    • Buspirone tablet, Teva, 15 mg, bottle, 500 count, NDC 00093-1003-05
    • Buspirone tablet, Teva, 30 mg, bottle, 60 count, NDC 00093-5200-06
    • Buspirone tablet, Teva, 5 mg, bottle, 100 count, NDC 00093-0053-01
    • Buspirone tablet, Teva, 5 mg, bottle, 500 count, NDC 00093-0053-05

Estimated Resupply Dates

    • Accord has all buspirone presentations on back order and the company cannot estimate a release date.
    • Teva has buspirone 10 mg tablets in 100 count bottles, 15 mg tablets in 100 count bottles, and 30 mg tablets in 500 count bottles on intermittent back order and the company is releasing supplies as they become available. The 10 mg tablets in 500 count bottles are on back order with an estimated release date in late-September 2019.
    • Zydus has all buspirone presentations on allocation.

Updated

Updated August 9, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created September 3, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins